The role of third-generation beta-blocking agents in chronic heart failure

Clinical Cardiology

Volumn 21, Issue 12 SUPPL. 1, 1998, Pages

  Bristow, Michael R ^a   Roden, Robert L ^a   Lowes, Brian D ^a   Gilbert, Edward M ^b   Eichhorn, Eric J ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adrenergic nervous system; Beta blocking agents; Heart failure; Third generation beta blocking agents

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CELIPROLOL; LABETALOL; METOPROLOL; NEBIVOLOL; PROPRANOLOL; XAMOTEROL;

ADRENERGIC SYSTEM; BETA ADRENERGIC RECEPTOR BLOCKING; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HOLTER MONITORING; HUMAN; RECEPTOR UPREGULATION; VASODILATATION;

EID: 0031760650     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960211303     Document Type: Conference Paper

References (76)

1. Eichhorn EJ, Bristow MR: Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 1996;94:2285-2296
2. Conn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552
3. Packer M, Carver JR, Chesebro JH, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, and the PROMISE investigators: Effect of milrinone on mortality in severe chronic heart failure. The prospective randomized milrinone survival evaluation (PROMISE). N Engl J Med 1991;325:1468-1475
4. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA, for the Enoximone Multi-center Trial Group: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990;82:774-780
5. Feldman A, Young J, Bourge R, Carson P, Jaski B, DeMets D, White BG, Cohn JN, for the VesT Investigators: Mechanism of increased mortality from vesnarinone in the severe heart failure trial (VesT). J Am Coll Cardiol 1997;29:64A
6. Packer M, Francis GS, Abrams J, Cobb FR, Eichhorn EJ, Giles TD, Kahl FR, Tandon PK: Oral milrinone increases the risk of sudden death in severe chronic heart failure: The PROMISE trial. Circulation 1991;84:II-310
7. Eichhorn EJ, Bristow MR: Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997;79:794-798
8. Bristow MR: Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:(11A):26L-40L
9. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM: β-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990;82:(suppl I)12-25
10. 1-adrenergic antagonist. J Cardiovasc Pharmacol 1998; 11(5):552-563
11. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR: Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17(suppl B): 8-16
12. Louis WJ, Drummer OH, Tung L-H: Actions of dilevalol on adrenoceptors. J Cardiovasc Pharmacol 1988;11(suppl 2):5-11
13. Rimele TJ, Aarhus LL, Lorenz RR, Rooke TW, Vanhoutte PM: Pharmacology of bucindolol in isolated canine vascular smooth muscle. J Pharmacol Exp Therap 1984;231(12):317-325
14. Hershberger RE, Wynn JR, Sundberg L, Bristow MR: Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990;15:959-967
15. 3-adrenergic receptor. Mol Pharmacol 1993;44:1094-1104
16. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CPL-H, Dupont AG, VanNueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Therap 1995;274:1067-1071
17. Tung LH, Jackman G, Campbell B, Louis S, lakovidis D, Louis WJ: Partial agonist activity of celiprolol. J Cardiovasc Pharmacol 1993;21:484-488
18. Jasper JR, Michel MC, Insel PA: Amplification of cyclic AMP generation reveals agonistic effects of certain β-adrenergic antagonists. Mol Pharmacol 1989;37:44-49
19. Böhm M, Schulz C, Schwinger RHG, Erdmann E: Positive inotropic effects due to partial agonistic activity of the β-adrenoceptor antagonist celiprolol following amplification of cAMP formation in failing human myocardium. J Cardiovasc Pharmacol 1992;20:479-489
20. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR: Carvedilol improves left ventricular function and symptoms in heart failure: A double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231
21. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR: Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825
22. Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feurstein R, Gu J-L, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Therap 1992;263:92-98
23. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, Müller-Beckmann B: Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992;19(suppl 1):68-80
24. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators: Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-1642
25. Deitchman D, Perhach JL, Snyder RW: β-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur J Pharm 1980;61:263-277
26. Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR: Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. Pharmacology 1998;56:30-36
27. Focaccio A, Larrabee P, Wollmering MM, Bristow MR: Xamoterol has agonist activity in end-stage failing human heart. J Am Coll Cardiol 1991;17:250A
28. Wollmering MM, Wiechmann RJ, Port JD, Hershberger RE, Focaccio A, Bristow MR: Dobutamine is a partial agonist with an intrinsic activity of 0.5 in human myocardium. J Am Coll Cardiol 1991;17:283A
29. The Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Lancet 1990;336:1-6
30. Silke B, Guy S, Riddell JG: Effects of β-adrenoceptor agonists and antagonists on heart-rate variability in normal subjects assessed using summary statistics and nonlinear procedures. J Cardiovasc Pharmacol 1997;30:817-823
31. Parati G, Ravogli A, Bragato R, Omboni S, Mutti E, Mancia G: Clinical and hemodynamic effects of celiprolol in essential hypertension. J Cardiovasc Pharmacol 1989;14(suppl 7):14-21
32. Chidiac P, Herbert TE, Valiquette M, Dennis M, Bouvier M: Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 1993;45:490-499
33. 2-adrenergic receptor. Mol Pharmacol 1993;45:390-394
34. Lowes BD, Chidiac P, Olsen S, Port JD, Bouvier M, Gilbert EM, Bristow MR: Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β-adrenergic receptor blocking agents. Circulation 1994;90(4):I-543
35. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816
36. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
37. 2-adrenergic receptor. Science 1994;264:582-586
38. Haber HL, Christopher LS, Gimple LW, Bergin JD, Subbiah ME, Jayaweera AR, Powers ER, Feldman MD: Why do patients with congestive heart failure tolerate the initiation of β-blocker therapy? Circulation 1993;88:1610-1619
39. Talwar KK, Bhargava B, Upasani PT, Verma S, Kamlakar T, Chopra P: Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. J Cardiac Failure 1996;2(4):273-277
40. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield B, Deitchman D, Brown M, Willard JE, Grayburn PA: Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990;82:473-483
41. 4L Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P: Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-1100
42. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Pass SM, Graybum PA, Hatfield BA, Marcoux LG, Malloy CR: Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320
43. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036
44. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR: Chronic β-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88:223-229
45. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR: Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol 1998;81:247-250
46. Anderson JL, Gilbert EM, O'Connell JB, Renlund D, Yanowitz F, Murray M, Roskelley M, Mealey P, Volkman K, Deitchman D, Bristow M: Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1991;17:1373-1381
47. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson Å, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446
48. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I: Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134-142
49. Heesch CM, Marcoux L, Hatfield B, Eichhorn EJ: Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Am J Cardiol 1995;75: 360-364
50. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM: Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther 1997;11:291-296
51. Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR: Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol 1996; 78:779-784
52. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N, on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060-1066
53. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Graybum PA, Eichhorn EJ: Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995;25: 1154-1161
54. Lowes BD, Gill EA, Abraham WT, Larrabee JR, Robertson AD, Bristow MR, Gilbert EM: The effect of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol, in press
55. Anderson B, Caidahl K, diLenarda A, Warren SE, Goss F, Waldenström A, Persson S, Wallentin I, Hjalmarson A, Waagstein F: Changes in early and late diastolic filling patterns induced by long-term adrenergic β-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996;94:673-682
56. Bristow MR, Port JD: β-adrenergic blockade in chronic heart failure. Scand Cardiovasc J 1998;47:45-55
57. Australia-New Zealand Heart Failure Research Collaborative Group: Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218
58. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B, for the SOLVD Investigators: Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995;91:2573-2581
59. Cohn JN: Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation 1995;91:2504-2507
60. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C-S, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NN, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation 1996;94:2793-2799
61. Krum H, Sakner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506
62. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, LeJemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA: Safety and efficacy of carvedilol in severe heart failure. J Cardiac Failure 1997;3:173-179
63. 2 adrenergic receptor mediated adenylate cyclase stimulation in non-failing and failing human ventricular myocardium. Mol Pharmacol 1989;35:295-303
64. s. Mol Pharmacol 1992;41: 889-893
65. Lubbe WF, Podzuweit T, Opie LH: Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: Implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992;19(7):1622-1633
66. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Bristow MR: β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441
67. Lowes BD, Abraham, WT, Dutcher DL, Roden RL, Crisman TS, Minobe W, Port JD, Larrabee P, Gilbert EM, Bristow MR: Comparative anti-adrenergic effects of carvedilol and metoprolol in a randomized, placebo-controlled-trial. Circulation 1996;94(suppl): I-664
68. Corr PB, Witkowski FX: Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion on ischemic myocardium. Circulation 1983;68(suppl I):16-24
69. CIBIS Investigators: A randomized trial of beta-blockade in heart failure: The cardiac insufficiency bisoprolol study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90:1765-1773
70. Fagerberg B: The International Steering Committee on behalf of the MERIT-HF Study Group: Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF). Am J Cardiol 1997;80(9B):54-58
71. The BEST Steering Committee: Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995;75:1220-1223
72. Metra M, Nardi M, Giubbini R, Cas LD: Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24(7): 1678-1687
73. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-2806
74. Uhlir O, Dvorak I, Gregor P, Malek I, Spinarova L, Vojacek J, Van Nueten L: Nebivolol in the treatment of cardiac failure: A double-blind controlled clinical trial. J Cardiac Failure 1997;3(4):271-276
75. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson A: Long-term β-blockade in dilated cardiomyopathy: Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-563
76. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP: Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. J Am Coll Cardiol 1994;23(4):943-950